Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010-2020).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 10 2023
18 10 2023
Historique:
received:
13
01
2023
accepted:
07
10
2023
medline:
23
10
2023
pubmed:
19
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Our study assessed DATASUS as a potential source for pharmacoepidemiologic studies in rheumatoid arthritis (RA) in the Brazilian population focusing on treatment patterns and determinants of initiating or switching to a novel therapy. This was a descriptive database study of RA patients with at least one claim of RA and ≥ 2 claims of disease-modifying anti-rheumatic drug (DMARD); conventional synthetic (cs), biologic (b) or targeted synthetic (ts) DMARD with more than 6 months of follow-up from 01-Jan-2010 to 31-Dec-2020. Analyses were stratified for SUS-exclusive and SUS+ private user cohorts. We identified 250,251 patients with RA in DATASUS: mean age of 58.4 years, majority female (83%) and white (58%). 62% were SUS-exclusive and 38% SUS+ private. Most common bDMARDs were adalimumab and etanercept. Age (adjusted odds ratio 1.78 [50+]; 95% CI 1.57-2.01), SUS exclusive status (0.53; 0.47-0.59), distance to clinic [160+ km] (0.57; 0.45-0.72), and pre-index csDMARD claims (1.23; 1.08-1.41) were independent predictors of initiating a novel oral tsDMARD. Switching from bDMARD to tsDMARD, associations were similar, except for the direction of associations for SUS exclusive status (adjusted hazard ratio 1.10; 1.03-1.18), distance to clinic (1.18; 1.03-1.35), and number of previous bDMARD (0.15; 0.14-0.16). DATASUS is a source suitable for treatment-related analyses in RA reflecting the public health system in Brazil.
Identifiants
pubmed: 37853013
doi: 10.1038/s41598-023-44389-9
pii: 10.1038/s41598-023-44389-9
pmc: PMC10584810
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17739Informations de copyright
© 2023. Springer Nature Limited.
Références
Front Pharmacol. 2022 Jan 14;12:789872
pubmed: 35115935
Rev Saude Publica. 2016 Aug 22;50:50
pubmed: 27556964
J Community Genet. 2013 Jul;4(3):355-75
pubmed: 22565417
Rev Bras Enferm. 2018;71(suppl 1):615-624
pubmed: 29562019
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Adv Rheumatol. 2021 Nov 24;61(1):70
pubmed: 34819172
Rheumatology (Oxford). 2014 Sep;53(9):1664-8
pubmed: 24729445
Int J Popul Data Sci. 2018 Nov 14;3(1):446
pubmed: 34095519
J Manag Care Spec Pharm. 2017 Aug;23(8):809-814
pubmed: 28737992
PLoS One. 2020 Mar 2;15(3):e0229768
pubmed: 32119696
Front Pharmacol. 2019 Sep 23;10:984
pubmed: 31607900
Rheumatol Int. 2021 May;41(5):863-877
pubmed: 33175207
BMC Musculoskelet Disord. 2011 Sep 19;12:204
pubmed: 21929807
Adv Ther. 2016 Aug;33(8):1347-59
pubmed: 27352377
PLoS One. 2018 Jun 21;13(6):e0199446
pubmed: 29928006
Expert Rev Clin Pharmacol. 2016 Jul;9(7):991-9
pubmed: 27181131
J Multidiscip Healthc. 2018 Jul 02;11:295-304
pubmed: 29997436
Value Health. 2019 Jun;22(6):739-749
pubmed: 31198192
Salud Publica Mex. 2011;53 Suppl 2:s120-31
pubmed: 21877078
Rheumatology (Oxford). 2010 Dec;49(12):2231-2
pubmed: 20439318
JAMA. 2018 Sep 4;320(9):867-868
pubmed: 30105359
Open Access Rheumatol. 2018 Aug 10;10:103-111
pubmed: 30127649
BMC Ophthalmol. 2021 Dec 13;21(1):430
pubmed: 34903203
Pharmacoepidemiol Drug Saf. 2022 Mar;31(3):343-352
pubmed: 34957616
Adv Rheumatol. 2020 Feb 27;60(1):16
pubmed: 32106881
Rev Bras Epidemiol. 2016 Jul-Sep;19(3):567-581
pubmed: 27849271
Adv Rheumatol. 2018 Jun 28;58(1):9
pubmed: 30657089
Patient Prefer Adherence. 2019 Jul 22;13:1199-1211
pubmed: 31413548
Front Pharmacol. 2021 Jul 21;12:628548
pubmed: 34366836
Front Public Health. 2021 Jun 15;9:642163
pubmed: 34211950